Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketotifen for Adverse Events in Peanut Desensitization
NCT01625715Phase 2Unknown
- Sponsor
- Gordon Sussman Clinical Research
- Start
- Jan 2011
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ketotifen in peanut allergy, sponsored by Gordon Sussman Clinical Research. Primary endpoint: Adverse Event leading to discontinuation at 12 months. Status: unknown.
02
Drugs
ketotifen
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT01625715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01625715.